1. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Issue 11 (November 2016) Authors: Bottomley, Andrew; Pe, Madeline; Sloan, Jeff; Basch, Ethan; Bonnetain, Franck; Calvert, Melanie; Campbell, Alicyn; Cleeland, Charles; Cocks, Kim; Collette, Laurence; Dueck, Amylou C; Devlin, Nancy; Flechtner, Hans-Henning; Gotay, Carolyn; Greimel, Eva; Griebsch, Ingolf; Groenvold, Mogens; Hamel, ... Journal: Lancet oncology Issue: Volume 17:Issue 11(2016:Nov.) Page Start: e510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Issue 3 (February 2015) Authors: Novello, Silvia; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Barrueco, José; Gaschler-Markefski, Birgit; Griebsch, Ingolf; Palmer, Michael; Reck, Martin; LUME-Lung 1 Study Group Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. (19th March 2019) Authors: Lim, Jonathan; Samuelsen, Carl; Golembesky, Amanda; Shrestha, Sulena; Wang, Li; Griebsch, Ingolf Journal: Future oncology Issue: Volume 15:Number 13(2019) Page Start: 1493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. (2nd January 2020) Authors: Samuelsen, Carl; Lim, Jonathan; Golembesky, Amanda; Shrestha, Sulena; Wang, Li; Griebsch, Ingolf Journal: Journal of medical economics Issue: Volume 23:Number 1(2020) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Issue 2 (February 2020) Authors: Coens, Corneel; Pe, Madeline; Dueck, Amylou C; Sloan, Jeff; Basch, Ethan; Calvert, Melanie; Campbell, Alicyn; Cleeland, Charles; Cocks, Kim; Collette, Laurence; Devlin, Nancy; Dorme, Lien; Flechtner, Hans-Henning; Gotay, Carolyn; Griebsch, Ingolf; Groenvold, Mogens; King, Madeleine; Kluetz, Paul ... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: e83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. Issue 10 (31st October 2014) Authors: Griebsch, Ingolf; Palmer, Michael; Fayers, Peter M; Ellis, Stuart Journal: BMJ open Issue: Volume 4:Issue 10(2014) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. (December 2018) Authors: Bottomley, Andrew; Pe, Madeline; Sloan, Jeff; Basch, Ethan; Bonnetain, Franck; Calvert, Melanie; Campbell, Alicyn; Cleeland, Charles; Cocks, Kim; Collette, Laurence; Dueck, Amylou C; Devlin, Nancy; Flechtner, Hans-Henning; Gotay, Carolyn; Greimel, Eva; Griebsch, Ingolf; Groenvold, Mogens; Hamel, ... Journal: Clinical trials Issue: Volume 15:Number 6(2018) Page Start: 624 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. (June 2017) Authors: Popat, Sanjay; Mellemgaard, Anders; Reck, Martin; Hastedt, Claudia; Griebsch, Ingolf Journal: Future oncology Issue: Volume 13:Number 13(2017) Page Start: 1159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. (February 2015) Authors: Popat, Sanjay; Mellemgaard, Anders; Fahrbach, Kyle; Martin, Alison; Rizzo, Maria; Kaiser, Rolf; Griebsch, Ingolf; Reck, Martin Journal: Future oncology Issue: Volume 11:Number 3(2015) Page Start: 409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Quality of life and congenital heart defects: comparing parent and professional values. Issue 5 (31st May 2006) Authors: Knowles, Rachel L; Griebsch, Ingolf; Bull, Catherine; Brown, Jacqueline; Wren, Christopher; Dezateux, Carol Journal: Archives of disease in childhood Issue: Volume 92:Issue 5(2007) Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗